SURMODICS INC logo

SRDX

SURMODICS INC

$22.87

Earnings Summary

Revenue
$24.93Mn
Net Profits
$-7.84Mn
Net Profit Margins
-31.46%

Highlights

Revenue:

SURMODICS INC’s revenue jumped 8.39% since last year same period to $24.93Mn in the Q4 2022. On a quarterly growth basis, SURMODICS INC has generated -4.06% fall in its revenue since last 3-months.

Net Profits:

SURMODICS INC’s net profit fell -178.91% since last year same period to $-7.84Mn in the Q4 2022. On a quarterly growth basis, SURMODICS INC has generated 46.75% jump in its net profits since last 3-months.

Net Profit Margins:

SURMODICS INC’s net profit margin fell -157.32% since last year same period to -31.46% in the Q4 2022. On a quarterly growth basis, SURMODICS INC has generated 44.49% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the SURMODICS INC post its latest quarter earnings

EPS Estimate Current Quarter
-0.67
EPS Estimate Current Year
-0.67

Highlights

EPS Estimate Current Quarter:

SURMODICS INC’s earning per share (EPS) estimates for the current quarter stand at -0.67 - a -48.89% fall from last quarter’s estimates.

EPS Estimate Current Year:

SURMODICS INC’s earning per share (EPS) estimates for the current year stand at -0.67.

Key Ratios

Key ratios of the SURMODICS INC post its Q4 2022 earnings

Return on Assets (ROA)
-0.09
Return on Equity (ROE)
-0.26

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. SURMODICS INC’s return on assets (ROA) stands at -0.09.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. SURMODICS INC’s return on equity (ROE) stands at -0.26.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-11-23
-0.45
-0.26
42.22%
2022-04-27
-0.34
-0.22
35.29%
2022-07-27
-0.38
-0.34
10.53%

Company Information

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Surmodics is pursuing highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company's expertise in proprietary surface technologies, along with enhanced device design, development, and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics' website is not part of this press release or part of any filings that the company makes with the SEC.

Organisation
SURMODICS INC
Headquarters
9924 West 74th Street, Eden Prairie, MN, United States, 55344-3523
Employees
447
Industry
Health Technology
CEO
Gary Maharaj